Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New ZealandGlobeNewsWire • 09/08/25
Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global ExpansionGlobeNewsWire • 08/06/25
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue DiagnosticGlobeNewsWire • 07/01/25
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth ControlGlobeNewsWire • 06/25/25
Femasys Names New Chief Commercial Officer to Drive Execution and Global GrowthGlobeNewsWire • 06/17/25
Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 LocationsGlobeNewsWire • 06/11/25
Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private PlacementGlobeNewsWire • 05/29/25
Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate UpdateGlobeNewsWire • 05/08/25
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate UpdateGlobeNewsWire • 03/27/25
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 LocationsGlobeNewsWire • 03/19/25
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in SpainGlobeNewsWire • 03/18/25
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical ApproachGlobeNewsWire • 03/13/25
Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical TrialsGlobeNewsWire • 02/25/25
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic DevicesGlobeNewsWire • 02/11/25
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth ControlGlobeNewsWire • 01/30/25
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility TreatmentGlobeNewsWire • 01/16/25
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility TreatmentGlobeNewsWire • 11/26/24
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate UpdateGlobeNewsWire • 11/12/24